Path towards mRNA delivery for cancer immunotherapy from bench to bedside

Chen, Wenfei; Zhu, Yining; He, Jinhan; Sun, Xun

doi:10.7150/thno.89247

Nanotheranostics 2025; 9(1): 38-51. Full text PDF

Nanotheranostics 2025; 9(1): 31-37. Full text PDF

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

open access Global reach, higher impact

Full Text | PDF

Theranostics 2024; 14(1):96-115. doi:10.7150/thno.89247 This issue Cite

Review

Path towards mRNA delivery for cancer immunotherapy from bench to bedside

Wenfei Chen^1,2, Yining Zhu^2,3, Jinhan He¹, Xun Sun^2✉

1. Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
3. Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.

Citation:

Chen W, Zhu Y, He J, Sun X. Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics 2024; 14(1):96-115. doi:10.7150/thno.89247. https://www.thno.org/v14p0096.htm

Other styles

Abstract

Messenger RNA (mRNA) has emerged as a promising therapeutic agent for the prevention and treatment of various diseases. mRNA vaccines, in particular, offer an alternative approach to conventional vaccines, boasting high potency, rapid development capabilities, cost-effectiveness, and safe administration. However, the clinical application of mRNA vaccines is hindered by the challenges of mRNA instability and inefficient in vivo delivery. In recent times, remarkable technological advancements have emerged to address these challenges, utilizing two main approaches: ex vivo transfection of dendritic cells (DCs) with mRNA and direct injection of mRNA-based therapeutics, either with or without a carrier. This review offers a comprehensive overview of major non-viral vectors employed for mRNA vaccine delivery. It showcases notable preclinical and clinical studies in the field of cancer immunotherapy and discusses important considerations for advancing these promising vaccine platforms for broader therapeutic applications. Additionally, we provide insights into future possibilities and the remaining challenges in mRNA delivery technology, emphasizing the significance of ongoing research in mRNA-based therapeutics.

Citation styles

APA

Chen, W., Zhu, Y., He, J., Sun, X. (2024). Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics, 14(1), 96-115. https://doi.org/10.7150/thno.89247.

ACS

Chen, W.; Zhu, Y.; He, J.; Sun, X. Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics 2024, 14 (1), 96-115. DOI: 10.7150/thno.89247.

NLM

Chen W, Zhu Y, He J, Sun X. Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics 2024; 14(1):96-115. doi:10.7150/thno.89247. https://www.thno.org/v14p0096.htm

CSE

Chen W, Zhu Y, He J, Sun X. 2024. Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics. 14(1):96-115.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.